Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with ...
Once submitted, we will try and place you in contact with a suitable Titrators / Titration Systems supplier within 48 hours.
Ascletis Pharma Inc. (HKEX: 1672, 'Ascletis') announces the presentation of three key studies at the American Diabetes ...
Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 4:00 PM EDTCompany ParticipantsJasbir Seehra ...
CRISPR screens generate actionable insights for drug discovery—explore how to optimize a screen, how to avoid pitfalls, and ...
Vietnam Investment Review on MSN
Ascletis presents obesity portfolio data including ASC30 clinical results at ADA 2026
HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific ...
Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level 1 This retrospective claims analysis, across >64,000 US adults, offered ...
Scientists at the University of Maryland, Baltimore County, have uncovered a crucial trick used by enteroviruses—the group behind diseases like polio, myocarditis, encephalitis, and even the common ...
Neurocrine Biosciences Presents New Clinically Meaningful Response Data On Treatment Of Tardive Dyskinesia, Reinforcing The Efficacy Of INGREZZA® (Valbenazine) Capsules Across A Broad Range Of ...
Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial ...
A mouse experiment has revealed that one parent’s epigenetic methylation pattern can rewrite the matching gene inherited from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results